The Effect Of Oral Ibandronate In Male Osteoporosis
Public ClinicalTrials.gov record NCT00397839. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Parallel, Placebo-controlled, Randomized (2:1) Double-blind Study of One Year Duration to Assess the Effect of Oral Ibandronate 150 mg Given Once-monthly Versus Placebo on LS BMD in Men With Osteoporosis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Male osteoporosis is a common and important clinical problem, associated with significant morbidity, mortality and societal expense. Approximately 10% of men =65 years of age are osteoporotic. The proposed study will evaluate efficacy and safety of oral ibandronate given 150 mg once-monthly for 12 months versus placebo in men with primary osteoporosis. Less frequent, once monthly, dosing is expected to improve patient's treatment adherence compared to a weekly dosing regimen.
Study identification
- NCT ID
- NCT00397839
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 135 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 30 Years and older
- Sex
- Male
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 31, 2006
- Primary completion
- Sep 30, 2008
- Completion
- Sep 30, 2008
- Last update posted
- Dec 20, 2009
2007 – 2008
United States locations
- U.S. sites
- 41
- U.S. states
- 26
- U.S. cities
- 39
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| GSK Investigational Site | Birmingham | Alabama | 35294-3708 | — |
| GSK Investigational Site | Tucson | Arizona | 85704 | — |
| GSK Investigational Site | Beverly Hills | California | 90211 | — |
| GSK Investigational Site | Greenbrae | California | 94904 | — |
| GSK Investigational Site | Oakland | California | 94609 | — |
| GSK Investigational Site | Palm Desert | California | 92260 | — |
| GSK Investigational Site | Walnut Creek | California | 94598 | — |
| GSK Investigational Site | Longmont | Colorado | 80501 | — |
| GSK Investigational Site | Clearwater | Florida | 33761 | — |
| GSK Investigational Site | Miami | Florida | 33136 | — |
| GSK Investigational Site | Miami | Florida | 33156 | — |
| GSK Investigational Site | Palm Harbor | Florida | 34684 | — |
| GSK Investigational Site | West Palm Beach | Florida | 33409 | — |
| GSK Investigational Site | Atlanta | Georgia | 30342 | — |
| GSK Investigational Site | Decatur | Georgia | 30033 | — |
| GSK Investigational Site | Gainsville | Georgia | 30501 | — |
| GSK Investigational Site | Champaign | Illinois | 61822 | — |
| GSK Investigational Site | Chicago | Illinois | 60611 | — |
| GSK Investigational Site | Peoria | Illinois | 61615 | — |
| GSK Investigational Site | Indianapolis | Indiana | 46250 | — |
| GSK Investigational Site | Kansas City | Kansas | 66160-7820 | — |
| GSK Investigational Site | Louisville | Kentucky | 40202 | — |
| GSK Investigational Site | South Portland | Maine | 04106 | — |
| GSK Investigational Site | Bathesda | Maryland | 20817 | — |
| GSK Investigational Site | Wheaton | Maryland | 20902 | — |
| GSK Investigational Site | Woodbury | Minnesota | 55125 | — |
| GSK Investigational Site | Springfield | Missouri | 65807 | — |
| GSK Investigational Site | Albuquerque | New Mexico | 87106 | — |
| GSK Investigational Site | Asheville | North Carolina | 28801 | — |
| GSK Investigational Site | Tulsa | Oklahoma | 74104 | — |
| GSK Investigational Site | Portland | Oregon | 97201 | — |
| GSK Investigational Site | Duncansville | Pennsylvania | 16635 | — |
| GSK Investigational Site | Providence | Rhode Island | 02908 | — |
| GSK Investigational Site | Charleston | South Carolina | 29407 | — |
| GSK Investigational Site | Dallas | Texas | 75216 | — |
| GSK Investigational Site | Richmond | Virginia | 23249 | — |
| GSK Investigational Site | Salem | Virginia | 24153 | — |
| GSK Investigational Site | Seattle | Washington | 98108 | — |
| GSK Investigational Site | Seattle | Washington | 98144 | — |
| GSK Investigational Site | Beckley | West Virginia | 25801 | — |
| GSK Investigational Site | Madison | Wisconsin | 53705 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00397839, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 20, 2009 · Synced Sep 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00397839 live on ClinicalTrials.gov.